- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SIRNAOMICS Aktie jetzt für 0€ handeln | |||||
| 22.07. | SIRNAOMICS-B (02257): RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR | - | HKEx | ||
| 03.07. | SIRNAOMICS-B (02257): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 2 | HKEx | ||
| 03.07. | SIRNAOMICS-B (02257): APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND INDEPENDENT NON-EXECUTIVE DIRECTOR | 1 | HKEx | ||
| 20.06. | SIRNAOMICS-B (02257): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 20.06. | SIRNAOMICS-B (02257): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 20, 2025 | - | HKEx | ||
| 05.06. | SIRNAOMICS-B (02257): TERMS OF REFERENCE FOR NOMINATION COMMITTEE UNDER THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 25.04. | SIRNAOMICS-B (02257): PROXY FORM | 1 | HKEx | ||
| 25.04. | SIRNAOMICS-B (02257): ANNUAL REPORT 2024 | - | HKEx | ||
| 25.04. | SIRNAOMICS-B (02257): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2024 | - | HKEx | ||
| 25.04. | SIRNAOMICS-B (02257): PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND BUY BACK SHARES, PROPOSED RE-ELECTION OF DIRECTORS, PROPOSED RE-APPOINTMENT ... | - | HKEx | ||
| 25.04. | SIRNAOMICS-B (02257): NOTICE OF ANNUAL GENERAL MEETING | 2 | HKEx | ||
| 23.04. | SIRNAOMICS-B (02257): CESSATION OF HONORARY SCIENTIFIC ADVISOR | - | HKEx | ||
| 27.03. | SIRNAOMICS-B (02257): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024 | - | HKEx | ||
| 18.03. | SIRNAOMICS-B (02257): REMEDIAL ACTIONS ON INTERNAL CONTROL WEAKNESSES AND DEFICIENCIES | - | HKEx | ||
| 17.03. | SIRNAOMICS-B (02257): NOTICE OF BOARD MEETING | - | HKEx | ||
| 19.02. | SIRNAOMICS-B (02257): CHANGE IN COMPOSITION OF BOARD COMMITTEE AND COMPLIANCE WITH LISTING RULES | 1 | HKEx | ||
| 17.02. | SIRNAOMICS-B (02257): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 2 | HKEx | ||
| 17.02. | SIRNAOMICS-B (02257): APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR, CHANGES IN COMPOSITION OF BOARD COMMITTEES AND UPDATE ON COMPLIANCE WITH LISTING ... | 1 | HKEx | ||
| 05.02. | SIRNAOMICS-B (02257): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 05.02. | SIRNAOMICS-B (02257): RESIGNATION OF NON-EXECUTIVE DIRECTOR, CHANGES IN COMPOSITION OF BOARD COMMITTEE AND CHANGE OF AUTHORIZED REPRESENTATIVE | 2 | HKEx |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 43,800 | -0,86 % | DZ BANK stuft QIAGEN NV auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat den fairen Wert für Qiagen von 47 auf 52 Euro angehoben und die Einstufung auf "Kaufen" belassen. Qiagen sei zurück auf dem Wachstumspfad, die operative... ► Artikel lesen | |
| EVOTEC | 7,046 | -4,50 % | Nach dem Prognose-Schock: Zoll-Rallye: Evotec-Aktien legen kräftig zu! | © Foto: Christian Charisius/dpa - dpa-BildfunkDie Aktie des Hamburger Wirkstoffforschers klettert am Montag auf den höchsten Stand seit Mitte Juni. Auch andere Pharmawerte profitieren von der Zolleinigung... ► Artikel lesen | |
| BIONTECH | 94,25 | +0,11 % | BioNTech SE: Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an LP.8.1 angepassten COVID-19-Impfstoff in der Europäischen Union | Daten zeigten, dass der an LP.8.1 angepasste COVID-19-Impfstoff verglichen mit den COVID-19-Impfstoffformulierungen 2024-2025 eine verbesserte Immunantwort gegen derzeit vorherrschende und neu auftretende... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,945 | 0,00 % | Recursion Pharmaceuticals: Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th | ||
| AVIDITY BIOSCIENCES | 36,650 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Completion of Enrollment for HARBOR, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory ... | -- Topline data readout from HARBOR study anticipated in Q2 2026 ---- Marketing application submissions for del-desiran including in U.S., EU and Japan anticipated... ► Artikel lesen | |
| PSYENCE BIOMEDICAL | 5,140 | 0,00 % | Pre-market Movers: VerifyMe, Psyence Biomedical, Pineapple Financial, Align Technology, Confluent | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green VerifyMe, Inc. (VRME) is up over 79% at $1.23.
Psyence... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,700 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025 | ||
| COGENT BIOSCIENCES | 11,410 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced ... | -- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 26,350 | 0,00 % | Summit Therapeutics stock rating reiterated by Cantor Fitzgerald | ||
| MODERNA | 25,800 | -0,42 % | Moderna erhält EU-Zulassung für aktualisierten COVID-19-Impfstoff | Moderna hat von der Europäischen Kommission die Zulassung für die aktualisierte Version seines COVID-19-Impfstoffs Spikevax erhalten. Die neue Formulierung richtet sich gegen die SARS-CoV-2-Variante... ► Artikel lesen | |
| DYNE THERAPEUTICS | 9,850 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights | - Expected cash runway extended into Q3 2027, beyond multiple potential inflection points including Dyne's first planned commercial launch in early 2027 - - Registrational Expansion Cohort of DELIVER... ► Artikel lesen | |
| BEAM THERAPEUTICS | 19,720 | 0,00 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
| BB BIOTECH | 35,600 | +2,89 % | BB Biotech schreibt im Q2 erneut Verlust | Schaffhausen - BB Biotech ist auch im zweiten Quartal 2025 in der Verlustzone geblieben. Als Hauptgrund nennt die Beteiligungsgesellschaft Wechselkurseffekte. Zwischen April und Juni schrieb BB Biotech... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 54,18 | -4,26 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies | The Breakthrough Therapy Designation (BTD) was granted based on the highly compelling results from the Phase 2 EMBOLD trial in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) The... ► Artikel lesen | |
| JANUX THERAPEUTICS | 24,030 | -0,83 % | Raymond James startet Coverage für Janux Therapeutics mit "Outperform"-Rating |
Das Unternehmen SIRNAOMICS LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,005 (+0,59 %) liegt der Kurs bei 0,850 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SIRNAOMICS LTD finden Sie auf Wallstreet Online.